Zobrazeno 1 - 10
of 37
pro vyhledávání: '"N. Lachenal"'
Autor:
S. B. Patil, M. Tamirat, K. Khazhidinov, E. Ardizzoni, M. Atger, A. Austin, E. Baudin, M. Bekhit, S. Bektasov, E. Berikova, M. Bonnet, R. Caboclo, M. Chaudhry, V. Chavan, S. Cloez, J. Coit, S. Coutisson, Z. Dakenova, B. C. De Jong, C. Delifer, S. Demaisons, J. M. Do, D. Dos Santos Tozzi, V. Ducher, G. Ferlazzo, M. Gouillou, U. Khan, M. Kunda, N. Lachenal, A. N. LaHood, L. Lecca, M. Mazmanian, H. McIlleron, M. Moreau, M. Moschioni, P. Nahid, E. Osso, L. Oyewusi, S. Panda, A. Pâquet, P. Thuong Huu, L. Pichon, M. L. Rich, P. Rupasinghe, N. Salahuddin, E. Sanchez Garavito, K. J. Seung, G. E. Velásquez, M. Vallet, F. Varaine, F. J. Yuya-Septoh, C. D. Mitnick, L. Guglielmetti
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicit
Externí odkaz:
https://doaj.org/article/2bb066dc17d74fc58700a32bcf0b5485
Autor:
L. Guglielmetti, E. Ardizzoni, M. Atger, E. Baudin, E. Berikova, M. Bonnet, E. Chang, S. Cloez, J. M. Coit, V. Cox, B. C. de Jong, C. Delifer, J. M. Do, D. Dos Santos Tozzi, V. Ducher, G. Ferlazzo, M. Gouillou, A. Khan, U. Khan, N. Lachenal, A. N. LaHood, L. Lecca, M. Mazmanian, H. McIlleron, M. Moschioni, K. O’Brien, O. Okunbor, L. Oyewusi, S. Panda, S. B. Patil, P. P. J. Phillips, L. Pichon, P. Rupasinghe, M. L. Rich, N. Saluhuddin, K. J. Seung, M. Tamirat, L. Trippa, M. Cellamare, G. E. Velásquez, S. Wasserman, P. J. Zimetbaum, F. Varaine, C. D. Mitnick
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-15 (2021)
Abstract Background Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many
Externí odkaz:
https://doaj.org/article/85bd589a0cd64486abc5fda915c2f7c5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Chinmay Laxmeshwar, Fatima Mamnoon, Petros Isaakidis, Augusto C Meneguim, Farah Naz Hossain, Taanya Mathur, Alpa Dalal, Stobdan Kalon, N Lachenal, Homa Mansoor, Sylvine Coutisson, Mrinalini Das, Pramila Singh, Roma Paryani, Gabriella Ferlazzo, Shilpa Ravi
Publikováno v:
Clinical Infectious Diseases. 73:e3496-e3504
Background The Médecins Sans Frontières Clinic in Mumbai, India, has been providing concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with drug-resistant tuberculosis (DR-TB) and limited therapeutic options, referr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c15c52ee5a6a74a1185881c25fb825a
https://doi.org/10.1093/cid/ciaa1577
https://doi.org/10.1093/cid/ciaa1577
Autor:
S.S. Islam, Kwonjune J. Seung, Mir Zeeshan Ali Khan, J Kliesckova, Y M Tassew, Nara Melikyan, Carole D. Mitnick, Naira Khachatryan, D Damtew, Francis Varaine, Helena Huerga, Anita Mesic, P Lenggogeni, H Karakozian, N Lachenal, M Mofolo, Saman Ahmed, Stephen Wanjala, S. Cloez, Cathy Hewison, Leonid Lecca, Aamir J. Khan, Christophe Perrin, Uzma Khan, M Richard, Palwasha Khan, K Herboczek, Mathieu Bastard, Stalz Charles Vilbrun, Alex Telnov, S Maretbayeva, Tinatin Kotrikadze, Molly F. Franke, Michael Rich
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 24:1081-1086
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major implementation challenges encountered in 17 endTB countries. We pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f7b136d4c251286bc9fdd23e541d83
https://doi.org/10.5588/ijtld.20.0141
https://doi.org/10.5588/ijtld.20.0141
Autor:
B. C. de Jong, S. B. Patil, M. Atger, N. Saluhuddin, Gabriella Ferlazzo, Vivian Cox, Helen McIlleron, Lawrence Oyewusi, Elmira A. Berikova, Aamir J. Khan, S. Wasserman, Michael Rich, M. Moschioni, D. Dos Santos Tozzi, Julia Coit, C. Delifer, L. Pichon, V. Ducher, Lorenzo Trippa, M. Gouillou, Lorenzo Guglielmetti, S. Panda, K. O’Brien, Matteo Cellamare, S. Cloez, Peter Zimetbaum, Carole D. Mitnick, Leonid Lecca, P. Rupasinghe, M. Mazmanian, Elisabeth Baudin, Uzma Khan, O. Okunbor, Maryline Bonnet, E. Chang, A. N. LaHood, Patrick P. J. Phillips, Gustavo E. Velásquez, Elisa Ardizzoni, M. Tamirat, Kwonjune J. Seung, N Lachenal, J. M. Do, Francis Varaine
Publikováno v:
Trials, vol 22, iss 1
Trials
Trials, BioMed Central, 2021, 22 (1), pp.651. ⟨10.1186/s13063-021-05491-3⟩
Trials, Vol 22, Iss 1, Pp 1-15 (2021)
Trials, 2021, 22 (1), pp.651. ⟨10.1186/s13063-021-05491-3⟩
Trials
Trials, BioMed Central, 2021, 22 (1), pp.651. ⟨10.1186/s13063-021-05491-3⟩
Trials, Vol 22, Iss 1, Pp 1-15 (2021)
Trials, 2021, 22 (1), pp.651. ⟨10.1186/s13063-021-05491-3⟩
Background Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476e2049884ad266a73b1f9c63d6be18
https://escholarship.org/uc/item/7fb6h2xd
https://escholarship.org/uc/item/7fb6h2xd
Autor:
Saman Ahmed, Uzma Khan, G Leblanc, S Coutisson, N Lachenal, Cathy Hewison, Michael Rich, A Krisnanda, J Makaka, A Stambekova, S.S. Islam, Andargachew Kumsa, Helena Huerga, Carole D. Mitnick, Kwonjune J. Seung, Nara Melikyan, K Zarli, S Abebe, S Padayachee, S de Guadalupe, A Reshid, Francis Varaine, S Adnan, Hakob Atshemyan, Elna Osso, P Nair, S Aiylchiev, Y Sahabutdinova, Palwasha Khan, N Lomtadze, Perea Moreno, B Kholikulov
Publikováno v:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 24(10)
SETTING: Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNITAID in April 2015, endTB (Expand New Drug markets for TB) facilitat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42d6649e4f967eb816317577f6dc6b47
https://pubmed.ncbi.nlm.nih.gov/33126944
https://pubmed.ncbi.nlm.nih.gov/33126944
Autor:
Yegiazaryan L, Naira Khachatryan, Helena Huerga, Atshemyan H, Mathieu Bastard, Chumburidze N, N. Kiria, Armen Hayrapetyan, Zaza Avaliani, Tinatin Kotrikadze, Francis Varaine, Kirakosyan O, Cathy Hewison, N Lachenal, Qayyum S
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 22:766-772
BACKGROUND AND SETTING Bedaquiline (BDQ) was initially only available through compassionate use programmes. OBJECTIVE To assess the effectiveness and safety of multidrug-resistant tuberculosis (MDR-TB) treatment containing BDQ. METHOD Retrospective a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7796642429b9d9f7eecda438c46b75ee
https://doi.org/10.5588/ijtld.17.0840
https://doi.org/10.5588/ijtld.17.0840
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.